LFG
AKBA icon

Larson Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Larson Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19K Buy
856
+82
+11% +$113 ﹤0.01% 3099
2025
Q4 		$1.25K Buy
+774
New +$1.62K ﹤0.01% 2900

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Larson Financial Group's AKBA Position: Q1 2026 in Review

Larson Financial Group increased its Akebia Therapeutics (AKBA) stake by 11% in Q1 2026, buying an estimated $113 and bringing the position to 856 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Larson Financial Group first reported a position in AKBA in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.25K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Larson Financial Group held 856 shares of Akebia Therapeutics worth $1.19K as of Q1 2026.
  • Larson Financial Group bought 82 Akebia Therapeutics shares in Q1 2026, an estimated $113.
  • Akebia Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3099 holding.
  • Larson Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Larson Financial Group's Akebia Therapeutics position peaked at $1.25K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.